Search

everythinglearnresearchcommunity

for

Search:↓

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

Activating TLR5 in the gut can extend lifespan and improve health in aged mice.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

A new enzyme in rats may help regulate hair growth.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

TRPA1 and TRPV1 channels don't affect mechanotransduction in rat sinus hair follicles.

SIG-1451 could be a promising new treatment for atopic dermatitis.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.

Dyclonine can effectively reduce skin issues by inhibiting the TRPV3 channel.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

TRPV3 channels are involved in skin processes and are affected by shear stress, influencing itch and mechanotransduction.

A new compound shows promise as a topical treatment for hair loss.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.